NCT06090474View on ClinicalTrials.gov

Multiple Dose Study to Evaluate Drug-drug Interactions, Safety and Tolerability of NDC-002 in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL

Enrollment

33

Participants

Timeline

Start Date

January 12, 2023

Primary Completion Date

March 15, 2023

Study Completion Date

March 15, 2023

Conditions

Stroke SequelaeStroke

Interventions

DRUG

NDC-002

Combination of NDC-002B and NDC-002C

Trial Locations (1)

Unknown

Insan Medical Foundation Metro Hospital, Anyang-si

All Listed Sponsors

lead

Dr. Noah Biotech Inc.

INDUSTRY